Table I.
Demography and clinical characteristics of the prePD-MG group.
| First author, year | Sex/Age, years | PD symptoms | PD treatment | Comorbidities | Interval | MG antibodies | Ocular symptoms | Dysphagia | Dysarthria | Head drop | MG treatment | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ueno, 1987 | M/55 | RT + Hm | THP, LD | DM | 5.5 years | AChR: P | Y | Y | N | Y | Pyd | (5) |
| Tasić, 1991 | M/74 | RT + R | THP, amantadine | Tuberculous lymphadenitis | 3 years | NR | Y | Y | Y | N | Pyd | (21) |
| Kao, 1993 | F/54 | R + RT + Hm + BK | THP, Sinemet | NR | 7 years | AChR: P | Y | Y | Y | Y | Pyd, CS | (6) |
| Levin, 2003 | M/76 | RT + R | LD | NR | 5 years | AChR: P | N | N | N | Y | Pyd, AZA | (8) |
| Levin, 2003 | M/62 | R + RT | LD, pergolide, selegiline, amantadine | NR | 4 years | AChR: P | Y | N | N | N | Pyd | (8) |
| Levin, 2003 | M/61 | R | LD | GD, hyperthyroidism | NR | NR | Y | N | N | N | Pyd | (8) |
| Fasano, 2008 | F/53 | RT + R + BK | NR | NR | 5 years | AChR: Ne; MuSK: Ne | N | N | N | Y | Pyd, CS, AZA, PE | (19) |
| Unal-Cevik, 2009 | M/80 | RT + R + BK | NR | Hypothyroidism, HPT | 4 years | AChR: Ne | N | N | N | Y | Pyd | (22) |
| Uludag, 2011 | M/66 | RT + R | LD, benserazide | HPT, COPD, hyperlipidemia | 9 years | AChR: P | N | N | N | Y | IVIG, Pyd | (10) |
| Lanfranconi, 2011 | M/70 | RT + BK + R + Hm | LD | NR | 3 years | AChR:Ne; MuSK: P | Y | Y | Y | N | CS | (11) |
| Zis, 2014 | M/64 | R | NR | HPT, RA | 5 years | AChR: P; Musk: Ne | N | N | N | Y | Pyd, CS | (20) |
| Neuman, 2014 | F/68 | RT + R + BK | LD | NR | 7 years | AChR: P | N | N | N | Y | Pyd, AZA, IVIG | (12) |
| Sciacca, 2016 | F/57 | NR | NR | NR | 9 years | NR | Y | N | N | N | Pyd | (18) |
| Sciacca, 2016 | M/60 | NR | NR | NR | 3 years | NR | Y | N | N | Y | Pyd | (18) |
| Sciacca, 2016 | M/67 | NR | NR | NR | 3 years | AChR: P | Y | N | N | N | Pyd | (18) |
| Tung-Chen, 2016 | F/71 | BK + Hm + R + RT | LD | Anemia | 19 years | AChR: Ne | Y | Y | Y | N | Pyd, CS, AZA, IVIG | (13) |
| Aiba, 2016 | F/71 | R + BK | LD | NR | 5 years | AChR: P | N | N | N | Y | Pyd, CS | (23) |
| Hogg, 2017 | M/75 | BK + Hm + R | NR | Myopathy | 3-4 months | AChR: P | Y | Y | Y | Y | Pyd | (24) |
| Urban, 2018 | M/76 | NR | NR | NR | 6 years | AChR: P | N | Y | N | N | Pyd, CS, IVIG, AZA | (25) |
| Urban, 2018 | M/90 | NR | NR | NR | 5 years | AChR: P | N | Y | N | N | Pyd, CS | (25) |
| Urban, 2018 | M/78 | NR | NR | NR | 5 years | AChR: P | N | Y | N | N | Pyd, CS. AZA | (25) |
| Urban, 2018 | M/74 | NR | NR | NR | 7 years | AChR: P | N | Y | Y | N | Pyd, IVIG, CS, AZA | (25) |
| Marano, 2019 | M/65 | RT + BK + R | LD | NR | 8 years | AChR: P | Y | Y | N | Y | Pyd, CS, AZA | (26) |
| Odajiu, 2019 | M/49 | BK + R + Hm | Stalevo, ropinirole rasagiline | Crohn's disease | 11 years | AChR: P | Y | N | N | N | Pyd | (9) |
| Odajiu, 2019 | F/64 | BK + RBD + Hm + R | Stalevo, pramipexole, rasagiline | HPT | 4 years | AChR: Ne | Y | Y | Y | N | Pyd | (9) |
| Odajiu, 2019 | M/52 | RT + BK + R | Stalevo, rasagiline, THP | DM, HPT | 3 years | AChR:Ne; MuSK: Ne | Y | N | N | N | Pyd | (9) |
| Alshaikh, 2021 | M/61 | NR | NR | Vitamin B12 deficiency | 6 years | AChR: P | Y | Y | Y | N | NR | (4) |
| Alshaikh, 2021 | M/61 | NR | NR | Neuropathy, vitamin B12 deficiency | 1 year | AChR: P | Y | Y | Y | Y | NR | (4) |
| Alshaikh, 2021 | M/82 | NR | NR | NR | NR | AChR: P | NR | Y | Y | N | NR | (4) |
| Current case | M/62 | RT + BK | LD, entacapone | None | 6 years | AChR: P; MuSK: Ne | Y | Y | N | Y | Pyd, CS, IVIG, tacrolimus (FK506) |
F, female; M, male; PD, Parkinson's disease; Hm, hypomimia; R, rigidity; RT, resting tremor; BK, bradykinesia; LD, levodopa; THP, trihexyphenidyl; RBD, rapid eye movement sleep behavior disorder; DM, diabetes mellitus; GD, Graves' disease; HPT, hypertension; RA, rheumatoid arthritis; COPD, chronic obstructive lung disease; MG, myasthenia gravis; AChR, acetylcholine receptor; MuSK, muscle-specific kinase; AZA, azathioprine; CS, prednisone/methylprednisolone; Pyd, pyridostigmine; IVIG, intravenous immunoglobulin; NR, not reported; P, positive; Ne, negative; Y, yes; N, No.